drugset / Trial / NCT03366324
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
Phase 1/2
Unknown
20 enrolled
Wuhan Sian Medical Technology Co., Ltd
Jingzhou Central Hospital · collabThe First People's Hospital of Yuhang District · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabXiangyang Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
For micro residual disease (MRD) positive patients who have undergone at least 2 cycles chemotherapies for their CD19+ B-cell malignancies, there would be much more risks for them to receive hematological stem cell transplantation (HSCT) than MRD- patients. In order to reduce HSCT-related adverse events for these kind of patients, investigators plan to conduct CAR-T therapies on them first to make them achieve MRD- statuses, and then transfer them to HSCT.
Timeline
- Start
- 2016-05-01
- Primary completion
- 2021-01-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells | Cell therapy | — | — |